Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:March 23, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:March 23, 2023Terminated
Condition(s):MelanomaLast Updated:April 15, 2021Unknown status
Condition(s):Metastatic MelanomaLast Updated:November 18, 2015Unknown status
Condition(s):Mesothelioma; Peritoneal MesotheliomaLast Updated:January 3, 2024Completed
Condition(s):Stage IIIC Skin Melanoma; Stage IV Skin MelanomaLast Updated:January 24, 2019Completed
Condition(s):Metastatic Malignant MelanomaLast Updated:May 13, 2015Completed
Condition(s):Hepatocellular Carcinoma (HCC)Last Updated:December 4, 2020Unknown status
Condition(s):Breast CancerLast Updated:December 13, 2023Active, not recruiting
Condition(s):Acute Myeloid Leukemia; Myelodysplastic Syndromes; Myeloproliferative Neoplasms; Chronic Myelomonocytic Leukemia; MyelofibrosisLast Updated:May 30, 2023Recruiting
Condition(s):MelanomaLast Updated:August 14, 2023Suspended
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.